Ingalls & Snyder LLC boosted its position in Eli Lilly And Co (NYSE:LLY) by 8.0% during the 4th quarter, Holdings Channel reports. The fund owned 17,227 shares of the company’s stock after acquiring an additional 1,275 shares during the quarter. Ingalls & Snyder LLC’s holdings in Eli Lilly And Co were worth $2,264,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Selective Wealth Management Inc. acquired a new stake in Eli Lilly And Co during the third quarter worth approximately $25,000. Enterprise Trust & Investment Co acquired a new stake in Eli Lilly And Co during the third quarter worth approximately $27,000. Garrett Wealth Advisory Group LLC acquired a new stake in Eli Lilly And Co during the third quarter worth approximately $29,000. Candriam Luxembourg S.C.A. raised its holdings in Eli Lilly And Co by 47.7% during the third quarter. Candriam Luxembourg S.C.A. now owns 270,304 shares of the company’s stock worth $30,000 after purchasing an additional 87,250 shares in the last quarter. Finally, Prestige Wealth Management Group LLC acquired a new stake in Eli Lilly And Co during the second quarter worth approximately $34,000. 76.45% of the stock is currently owned by hedge funds and other institutional investors.
In related news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly And Co stock in a transaction on Monday, January 13th. The shares were sold at an average price of $138.92, for a total value of $28,478,600.00. Following the transaction, the insider now directly owns 113,741,549 shares in the company, valued at approximately $15,800,975,987.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jackson P. Tai acquired 1,861 shares of the stock in a transaction that occurred on Thursday, October 24th. The stock was purchased at an average price of $107.49 per share, for a total transaction of $200,038.89. Following the completion of the transaction, the director now owns 56,440 shares in the company, valued at $6,066,735.60. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 8,405 shares of company stock worth $909,004 and sold 1,780,504 shares worth $219,697,912. Insiders own 0.11% of the company’s stock.
Shares of Eli Lilly And Co stock opened at $141.11 on Thursday. The firm’s fifty day simple moving average is $127.65 and its 200-day simple moving average is $115.42. The stock has a market capitalization of $135.04 billion, a price-to-earnings ratio of 25.43, a PEG ratio of 1.84 and a beta of 0.20. Eli Lilly And Co has a 12 month low of $101.36 and a 12 month high of $141.69. The company has a debt-to-equity ratio of 4.09, a current ratio of 1.17 and a quick ratio of 0.88.
Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Wednesday, October 23rd. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.43 by $0.05. The business had revenue of $5.48 billion for the quarter, compared to analysts’ expectations of $5.50 billion. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The company’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.39 EPS. Analysts anticipate that Eli Lilly And Co will post 5.8 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 14th will be issued a $0.74 dividend. This represents a $2.96 dividend on an annualized basis and a dividend yield of 2.10%. This is a boost from Eli Lilly And Co’s previous quarterly dividend of $0.65. The ex-dividend date is Thursday, February 13th. Eli Lilly And Co’s payout ratio is presently 46.49%.
A number of analysts have weighed in on the stock. Morgan Stanley raised shares of Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $116.00 to $150.00 in a report on Wednesday, December 18th. They noted that the move was a valuation call. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly And Co from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. TheStreet raised shares of Eli Lilly And Co from a “c+” rating to a “b-” rating in a report on Friday, November 8th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $143.00 target price on shares of Eli Lilly And Co in a report on Monday, December 2nd. Finally, Argus lifted their target price on shares of Eli Lilly And Co from $145.00 to $165.00 and gave the company a “buy” rating in a report on Monday, December 30th. Five analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $135.67.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: Bid-Ask Spread
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.